Successful Treatment of Refractory Immune-Mediated Colitis and Duodenitis with Tofacitinib
As ICIs are increasingly used, the incidence of refractory IMC and other immune-related toxicities is expected to rise. This case highlights the need for further studies to establish the optimal use of tofacitinib in refractory IMC and duodenitis.
Authors
- Shigeki Tamura (ORCID: https://orcid.org/0000-0003-0930-576X)
- Takuma Higurashi (ORCID: https://orcid.org/0000-0002-1815-4396)
- Noboru Misawa (ORCID: https://orcid.org/0000-0002-9272-174X)
- Shoji Yamanaka (ORCID: https://orcid.org/0000-0003-0925-8633)
- Kosuke Inoue (ORCID: https://orcid.org/0000-0001-9614-8103)
- Atsushi Nakajima (ORCID: https://orcid.org/0000-0003-3811-9704)
- Masato Yoneda
- Hitomi Suzuki (ORCID: https://orcid.org/0009-0002-7619-8933)
- Chikahide Hori
Institutions
- Yokohama City University Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Case Reports in Gastroenterology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1159/000547424
- Citations
- 1
- Primary Topic
- Microscopic Colitis
- Type
- article
- Field-Weighted Citation Impact
- 1.35